Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc has appointed Dr. Christina Coughlin as its new CEO, effective May 1, 2024. Dr. Coughlin brings extensive experience in oncology and biopharmaceuticals, having served as a board member and head of R&D, where she advanced the development of their pre|CISION platform for cancer treatment. The company is poised for its next clinical development phase, focusing on delivering innovative cancer therapies and enhancing shareholder value.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
